Therapeutic Interventions for COVID-19: a Living Overview of Reviews

Overview

Journal Ther Adv Respir Dis

Publisher Sage Publications

Specialties Pharmacology
Pulmonary Medicine

Date 2020 Dec 16

PMID 33326318

Citations 5

Authors

Malahat Khalili

Maryam Chegeni

Sara Javadi

Mehrdad Farokhnia

Hamid Sharifi

Mohammad Karamouzian

Affiliations

Soon will be listed here.

Abstract

Background: Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide, but safe and effective treatment options remain unavailable. Numerous systematic reviews of varying qualities have tried to summarize the evidence on the available therapeutic interventions for COVID-19. This overview of reviews aims to provide a succinct summary of the findings of systematic reviews on different pharmacological and non-pharmacological therapeutic interventions for COVID-19.

Methods: We searched PubMed, Embase, Google Scholar, Cochrane Database of Systematic Reviews, and WHO database of publications on COVID-19 from 1 December 2019 through to 11 June 2020 for peer-reviewed systematic review studies that reported on potential pharmacological or non-pharmacological therapies for COVID-19. Quality assessment was completed using A MeaSurement Tool to Assess systematic Reviews-2 (AMSTAR-2) measure.

Results: Out of 816 non-duplicate studies, 45 were included in the overview. Antiviral and antibiotic agents, corticosteroids, and anti-malarial agents were the most common drug classes used to treat COVID-19; however, there was no direct or strong evidence to support their efficacy. Oxygen therapy and ventilatory support was the most common non-pharmacological supportive care. The quality of most of the included reviews was rated as low or critically low.

Conclusion: This overview of reviews demonstrates that although some therapeutic interventions may be beneficial to specific subgroups of COVID-19 patients, the available data are insufficient to strongly recommend any particular treatment option to be used at a population level. Future systematic reviews on COVID-19 treatments should adhere to the recommended systematic review methodologies and ensure that promptness and comprehensiveness are balanced.

Citing Articles

Rise of monkeypox: Lessons from COVID-19 pandemic to mitigate global health crises.

Ennab F, Nawaz F, Narain K, Nchasi G, Essar M Ann Med Surg (Lond). 2022; 79:104049.

PMID: 35757311 PMC: 9217059. DOI: 10.1016/j.amsu.2022.104049.

Effectiveness of Systemic Corticosteroids Therapy for Nonsevere Patients With COVID-19: A Multicenter, Retrospective, Longitudinal Cohort Study.

Chen Z, Yin X, Tan X, Wang J, Jiang N, Tian M Value Health. 2022; 25(5):709-716.

PMID: 35219601 PMC: 8866099. DOI: 10.1016/j.jval.2021.12.013.

Unmet need for COVID-19 vaccination coverage in Kenya.

Muchiri S, Muthee R, Kiarie H, Sitienei J, Agweyu A, Atkinson P Vaccine. 2022; 40(13):2011-2019.

PMID: 35184925 PMC: 8841160. DOI: 10.1016/j.vaccine.2022.02.035.

The Potential Drug Interactions Between Multiple Sclerosis and COVID-19 Therapies.

Goncuoglu C, Bayraktar Ekincioglu A, Tuncer A Turk J Pharm Sci. 2022; 18(6):665-666.

PMID: 34978395 PMC: 8744437. DOI: 10.4274/tjps.galenos.2021.92892.

Evidence of SARS-CoV-2 Transmission Through the Ocular Route.

Qu J, Xie H, Zhang M Clin Ophthalmol. 2021; 15:687-696.

PMID: 33658750 PMC: 7920625. DOI: 10.2147/OPTH.S295283.

References

Alijotas-Reig J, Esteve-Valverde E, Belizna C, Selva-OCallaghan A, Pardos-Gea J, Quintana A . Immunomodulatory therapy for the management of severe COVID-19. Beyond the anti-viral therapy: A comprehensive review. Autoimmun Rev. 2020; 19(7):102569. PMC: 7252146. DOI: 10.1016/j.autrev.2020.102569. View

Bhimraj A, Morgan R, Shumaker A, Lavergne V, Baden L, Cheng V . Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19. Clin Infect Dis. 2020; . PMC: 7197612. DOI: 10.1093/cid/ciaa478. View

Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J . Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020; 323(16):1582-1589. PMC: 7101507. DOI: 10.1001/jama.2020.4783. View

Pascarella G, Strumia A, Piliego C, Bruno F, Del Buono R, Costa F . COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288(2):192-206. PMC: 7267177. DOI: 10.1111/joim.13091. View

Liu W, Zhou P, Chen K, Ye Z, Liu F, Li X . Efficacy and safety of antiviral treatment for COVID-19 from evidence in studies of SARS-CoV-2 and other acute viral infections: a systematic review and meta-analysis. CMAJ. 2020; 192(27):E734-E744. PMC: 7828899. DOI: 10.1503/cmaj.200647. View

Jorgensen S, Kebriaei R, Dresser L . Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19. Pharmacotherapy. 2020; 40(7):659-671. PMC: 7283864. DOI: 10.1002/phar.2429. View

Duan K, Liu B, Li C, Zhang H, Yu T, Qu J . Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020; 117(17):9490-9496. PMC: 7196837. DOI: 10.1073/pnas.2004168117. View

Pieper D, Antoine S, Mathes T, Neugebauer E, Eikermann M . Systematic review finds overlapping reviews were not mentioned in every other overview. J Clin Epidemiol. 2014; 67(4):368-75. DOI: 10.1016/j.jclinepi.2013.11.007. View

Funck-Brentano C, Salem J . Chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous?. Lancet. 2020; . PMC: 7255131. DOI: 10.1016/S0140-6736(20)31174-0. View

10.

Lunny C, Brennan S, McDonald S, McKenzie J . Toward a comprehensive evidence map of overview of systematic review methods: paper 1-purpose, eligibility, search and data extraction. Syst Rev. 2017; 6(1):231. PMC: 5698938. DOI: 10.1186/s13643-017-0617-1. View

11.

Rodrigo C, Fernando S, Rajapakse S . Clinical evidence for repurposing chloroquine and hydroxychloroquine as antiviral agents: a systematic review. Clin Microbiol Infect. 2020; 26(8):979-987. PMC: 7250111. DOI: 10.1016/j.cmi.2020.05.016. View

12.

Tang W, Cao Z, Han M, Wang Z, Chen J, Sun W . Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020; 369:m1849. PMC: 7221473. DOI: 10.1136/bmj.m1849. View

13.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

14.

Liu M, Gao Y, Yuan Y, Yang K, Shi S, Zhang J . Efficacy and Safety of Integrated Traditional Chinese and Western Medicine for Corona Virus Disease 2019 (COVID-19): a systematic review and meta-analysis. Pharmacol Res. 2020; 158:104896. PMC: 7211759. DOI: 10.1016/j.phrs.2020.104896. View

15.

Rabby M . Current Drugs with Potential for Treatment of COVID-19: A Literature Review. J Pharm Pharm Sci. 2020; 23(1):58-64. DOI: 10.18433/jpps31002. View

16.

Gbinigie K, Frie K . Should chloroquine and hydroxychloroquine be used to treat COVID-19? A rapid review. BJGP Open. 2020; 4(2). PMC: 7330219. DOI: 10.3399/bjgpopen20X101069. View

17.

Hernandez A, Roman Y, Pasupuleti V, Barboza J, White C . Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review. Ann Intern Med. 2020; 173(4):287-296. DOI: 10.7326/M20-2496. View

18.

Borges do Nascimento I, Cacic N, Abdulazeem H, von Groote T, Jayarajah U, Weerasekara I . Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. J Clin Med. 2020; 9(4). PMC: 7230636. DOI: 10.3390/jcm9040941. View

19.

Lippi G, Sanchis-Gomar F, Henry B . Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med. 2020; 8(7):497. PMC: 7210187. DOI: 10.21037/atm.2020.03.157. View

20.

Valk S, Piechotta V, Chai K, Doree C, Monsef I, Wood E . Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid review. Cochrane Database Syst Rev. 2020; 5:CD013600. PMC: 7271896. DOI: 10.1002/14651858.CD013600. View